SCHEMBL6449443

SCHEMBL6449443

CON=CCCc1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
TAAR1 Q96RJ0 3/20 0.41
AOC3 Q16853 2/20 0.39
PTGS1 P23219 1/20 0.37
PTGS2 P35354 1/20 0.37
KCNH2 Q12809 1/20 0.36
TMEM97 Q5BJF2 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
MAOB P27338 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
ELOVL1 Q9BW60 1/20 0.36
MEN1 O00255 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
KMT2A Q03164 1/20 0.36
IDO1 P14902 1/20 0.35
AGXT P21549 1/20 0.35
AOC2 O75106 1/20 0.35
MAOA P21397 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6449435 1.00 KDM4E (0.46) KDM4ETAAR1AOC3PTGS1PTGS2
SCHEMBL27596114 0.89 KDM4E (0.44) KDM4ETAAR1AOC3PTGS1PTGS2
SCHEMBL1444575 0.81 KDM4E (0.49) KDM4ETAAR1MAOBIDO1AGXT
SCHEMBL6076750 0.81 KDM4E (0.49) KDM4ETAAR1MAOBIDO1AGXT
SCHEMBL12756968 0.81 ALDH1A1 (0.42) KDM4ETAAR1L3MBTL1POLBMAPT
SCHEMBL27804585 0.75 TAAR1 (0.45) TAAR1AOC3PTGS1PTGS2MAOB
SCHEMBL6870419 0.74 MEN1 (0.47) TAAR1KCNH2TMEM97SIGMAR1MEN1
SCHEMBL6870416 0.74 MEN1 (0.47) TAAR1KCNH2TMEM97SIGMAR1MEN1
SCHEMBL27961105 0.73 AOC2 (0.39) KDM4ETAAR1AOC3PTGS1PTGS2
SCHEMBL755405 0.72 TAAR1 (0.42) KDM4ETAAR1AOC3PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1617849-A HIV integrase inhibitors BRISTOL MYERS SQUIBB CO (US) 2005-05-18 CN disclosed
US-6890942-B2 Acyl sulfonamides as inhibitors of HIV integrase BRISTOL-MYERS SQUIBB COMPANY (US) 2005-05-10 US disclosed
US-20050004232-A1 Acyl sulfonamides as inhibitors of HIV integrase BRISTOL-MYERS SQUIBB COMPANY 2005-01-06 US disclosed
WO-2004103278-A2 ACYL SULFONAMIDES AS INHIBITORS OF HIV INTEGRASE BRISTOL-MYERS SQUIBB COMPANY (US) 2004-12-02 WO disclosed
EP-1467695-A2 HIV INTEGRASE INHIBITORS Bristol-Myers Squibb Company (US) 2004-10-20 EP disclosed
US-6777440-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-08-17 US disclosed
US-20030176495-A1 HIV Integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2003-09-18 US disclosed
WO-2003049690-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004232-A1 Acyl sulfonamides as inhibitors of HIV integrase ACSS2, ARSA, ASS1 KDM4E 689/4885TAAR1 4077/4885AOC3 4283/4885
US-20030176495-A1 HIV Integrase inhibitors MAPT, RIF1, HPRT1 KDM4E 1398/4885TAAR1 3904/4885AOC3 4651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.